This content is from: Patents

Generics would be shut out of PTAB under Hatch amendment

The Hatch-Waxman Integrity Act of 2018 would require a generic manufacturer wishing to challenge a brand-name drug patent to choose between Hatch-Waxman litigation and IPR, which one observer describes as a “Hobson’s choice”

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.

REQUEST ACCESS

Are you already an Managing IP subscriber? Login here

Instant access to all of our content. Membership Options | One Week Trial